- Home
- CLLS vs SABA Comparison
CLLS vs SABA Comparison
Compare CLLS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SABA
- Stock Information
- Founded
- CLLS 1999
- SABA 1988
- Country
- CLLS France
- SABA United States
- Employees
- CLLS N/A
- SABA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- CLLS Health Care
- SABA
- Exchange
- CLLS Nasdaq
- SABA Nasdaq
- Market Cap
- CLLS 143.4M
- SABA 246.4M
- IPO Year
- CLLS 2007
- SABA N/A
- Fundamental
- Price
- CLLS $1.61
- SABA $9.19
- Analyst Decision
- CLLS Buy
- SABA
- Analyst Count
- CLLS 1
- SABA 0
- Target Price
- CLLS $4.00
- SABA N/A
- AVG Volume (30 Days)
- CLLS 52.1K
- SABA 290.0K
- Earning Date
- CLLS 08-05-2025
- SABA 01-01-0001
- Dividend Yield
- CLLS N/A
- SABA 12.91%
- EPS Growth
- CLLS N/A
- SABA N/A
- EPS
- CLLS N/A
- SABA N/A
- Revenue
- CLLS $54,747,000.00
- SABA N/A
- Revenue This Year
- CLLS $48.52
- SABA N/A
- Revenue Next Year
- CLLS $5.17
- SABA N/A
- P/E Ratio
- CLLS N/A
- SABA N/A
- Revenue Growth
- CLLS 351.26
- SABA N/A
- 52 Week Low
- CLLS $1.10
- SABA $3.64
- 52 Week High
- CLLS $2.43
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- CLLS 61.29
- SABA 63.58
- Support Level
- CLLS $1.56
- SABA $9.09
- Resistance Level
- CLLS $1.49
- SABA $9.27
- Average True Range (ATR)
- CLLS 0.09
- SABA 0.11
- MACD
- CLLS 0.02
- SABA -0.00
- Stochastic Oscillator
- CLLS 86.67
- SABA 70.27
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.